Quiver Bioscience

Quiver Bioscience, based in the US, is a biotechnology firm focused on developing AI-driven therapeutics for neurological diseases, utilizing advanced technologies to design effective treatments targeting genetic and molecular pathways. Founded in 2013 in Cambridge, US, Quiver Bioscience specializes in biotechnology solutions for neurological conditions. The company has engaged in one notable deal, with their most recent funding round occurring on April 13, 2026. Founded by individuals with a background in biotechnology, Quiver has been focusing on its innovative approach to therapeutic development.

Quiver Bioscience specializes in the development of AI-driven therapeutics aimed at addressing neurological diseases. The company’s core product offerings include a pipeline of antisense oligonucleotide (ASO) therapies targeting specific genetic and molecular pathways in conditions such as chronic pain, Dup15q syndrome, and various forms of epilepsy. Their innovative approach integrates scalable biology and advanced technology to identify novel therapeutic targets, ensuring that human relevance is prioritized from inception. The therapeutic candidates, including genetically-validated targets like Nav1.

7 and UBE3A, are designed to offer safer and more effective central nervous system (CNS) drug options. Quiver's products are primarily aimed at healthcare providers and pharmaceutical partners in North America and Europe, where there exists a significant need for effective treatments in the realm of neurological disorders. Quiver Bioscience generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies, focusing on the development and commercialization of its novel therapeutics. The company engages in B2B transactions, forming alliances that may involve licensing agreements or co-development contracts.

These partnerships typically outline shared responsibilities in research, development, and potential profit-sharing arrangements upon successful product commercialization. The revenue structure is built around the delivery of therapeutic candidates, including their flagship ASO products, which are still in various stages of discovery and pre-clinical testing. The company's revenue model emphasizes long-term partnerships rather than direct consumer sales, aligning with its goal of transforming therapeutic landscapes for neurological diseases. In April 2026, Quiver Bioscience raised an undisclosed amount of venture funding from new investor Porta family.

The funding will be allocated for the further development of its UBE3A ASO Therapeutic Program aimed at treating Dup15q Syndrome. The company is also exploring opportunities to expand its product offerings and enhance its therapeutic portfolio, targeting additional neurological disorders. Quiver aims to leverage this recent investment to accelerate its research initiatives and solidify its presence in both North American and European markets, where demand for effective neurological treatments continues to grow.